Tariffs and China Will Weigh on Thermo Fisher's Near-Term Results

While Thermo Fisher is weathering the pullback in global biopharmaceutical spending and China softness better than most of its peers, it is still not immune to the overall softness in the life science market. Having an unmatched portfolio of products, resources, and manufacturing capabilities have allowed the firm to retain and grow its wallet share among its customers across all channels. We expect the current budget-constrained environment to stay suppressed this year, but return to more normalized growth in 2026. Thermo Fisher remains in a great position to leverage its share gains in the biopharma channel and capitalize on strong long-term demand.